Acumen Pharmaceuticals, Inc. (ABOS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Acumen Pharmaceuticals, Inc. (ABOS) closed at USD 1.75 on 2026-10-14, a change of -23.8 % over the past year, with a market capitalization of USD 120.77M.

Acumen Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Acumen Pharmaceuticals, Inc. key figures

Previous close

USD 1.75 (2026-10-14)

1-year change

-23.8 %

Market cap

USD 120.77M

Enterprise value

USD 42.22M

P/E ratio (trailing)

-1.02

P/E ratio (forward)

-1.17

EPS (trailing)

-1.64

EPS (forward)

-1.43

PEG ratio

n/a

Price to book

2.11

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.26

Employees

60

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Acumen Pharmaceuticals, Inc. and compare it with other stocks.